Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Share-based Compensation: 2020-2025

Historic Share-based Compensation for Xeris Biopharma Holdings (XERS) over the last 5 years, with Sep 2025 value amounting to $7.6 million.

  • Xeris Biopharma Holdings' Share-based Compensation rose 12.93% to $7.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.7 million, marking a year-over-year increase of 17.99%. This contributed to the annual value of $18.4 million for FY2024, which is 71.36% up from last year.
  • Per Xeris Biopharma Holdings' latest filing, its Share-based Compensation stood at $7.6 million for Q3 2025, which was up 52.62% from $5.0 million recorded in Q2 2025.
  • In the past 5 years, Xeris Biopharma Holdings' Share-based Compensation ranged from a high of $7.6 million in Q3 2025 and a low of $2.5 million during Q3 2023.
  • For the 3-year period, Xeris Biopharma Holdings' Share-based Compensation averaged around $4.2 million, with its median value being $3.8 million (2024).
  • Per our database at Business Quant, Xeris Biopharma Holdings' Share-based Compensation fell by 22.33% in 2023 and then soared by 175.46% in 2024.
  • Xeris Biopharma Holdings' Share-based Compensation (Quarterly) stood at $2.7 million in 2021, then climbed by 0.84% to $2.8 million in 2022, then climbed by 0.04% to $2.8 million in 2023, then climbed by 29.92% to $3.6 million in 2024, then climbed by 12.93% to $7.6 million in 2025.
  • Its Share-based Compensation stands at $7.6 million for Q3 2025, versus $5.0 million for Q2 2025 and $4.4 million for Q1 2025.